Clinical trials: Heart Failure With Moderately Reduced Ejection Fraction
Heart Failure, Heart Failure With Preserved Ejection Fraction
Assessment of CCM in HF With Higher Ejection Fraction
The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.
- Conditions
- Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Moderately Reduced Ejection Fraction
- Trial name
- AIM HIGHer (NCT05064709)
- Testing
- Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System, OPTIMIZER™ Smart Mini System
- Where
- 67 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Impulse Dynamics
Heart Failure With Moderately Reduced Ejection Fraction
The Effect of Sacubitril/Valsartan Versus Ramipril on Left Ventricular Function and Remodeling in Patients With Ischemic Heart Failure With Mid-range Ejection Fraction
Heart failure with moderately reduced ejection fraction (HFmrEF) is a frequent disease associated with significant morbidity and mortality and therefore requires effective therapies that may improve clinical outcomes.
- Trial name
- CRACOVIA-HF (NCT05508035)
- Testing
- Sacubitril / Valsartan, Ramipril
- Where
- Poland
- Volunteers
- 488 people
- Sponsor
- John Paul II Hospital, Krakow